Bone anabolic treatments better than bisphosphonates for fracture prevention among postmenopausal women.
A new study found that bone anabolic therapies can be used for post-menopausal women with high risk for bone fractures as they were found to be superior to bisphosphonates in preventing clinical and vertebral fractures, regardless of the baseline risk factors. The study results were published in the journal The BMJ.
Osteoporosis is a common condition seen in post-menopausal women. There are multiple treatment algorithms for the management of it. Though most of them target bone mineral density, preventing fractures is the most relevant one. As previous literature has shown multiple treatment options researchers conducted a systematic review, network meta-analysis, and meta-regression analysis of various randomized clinical trials to review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterize the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors.
Between January 1996 and November 2021, data were extracted from all randomized controlled trials from Medline, Embase, and Cochrane Library to identify all non-Asian postmenopausal women with no age restriction, with interventions targeting bone quality in a broad perspective. 69 trials were included (>80 000 patients). Measuring clinical fractures was the primary outcome. Secondary outcomes were vertebral, non-vertebral, hip, and major osteoporotic fractures, all-cause mortality, adverse events, and serious cardiovascular adverse events.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.